Get the Stockscreener App
6.03
1.17%
0.07
After Hours:
6.04
0.010
+0.17%
Design Therapeutics Inc stock is traded at $6.03, with a volume of 126.14K.
It is up +1.17% in the last 24 hours and up +21.08% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
See More
Previous Close:
$5.96
Open:
$5.95
24h Volume:
126.14K
Relative Volume:
1.02
Market Cap:
$343.40M
Revenue:
-
Net Income/Loss:
$-66.86M
P/E Ratio:
-5.025
EPS:
-1.2
Net Cash Flow:
$-58.82M
1W Performance:
-6.51%
1M Performance:
+21.08%
6M Performance:
+21.57%
1Y Performance:
+3.25%
1-Day Range:
$5.90
$6.164
1-Week Range:
$5.65
$6.647
52-Week Range:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
6.03 | 349.09M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Design Therapeutics Inc. stock momentum explainedJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - Newser
Published on: 2025-09-12 17:41:40 - Newser
Can machine learning forecast Design Therapeutics Inc. recovery2025 Dividend Review & Accurate Buy Signal Alerts - Newser
Quantitative breakdown of Design Therapeutics Inc. recent moveQuarterly Trade Report & Daily Oversold Stock Bounce Ideas - Newser
What does recent volatility data suggest for Design Therapeutics Inc.2025 Trade Ideas & Daily Oversold Stock Bounce Ideas - Newser
Volatility clustering patterns for Design Therapeutics Inc.Bull Run & Risk Controlled Swing Trade Alerts - Newser
Detecting price anomalies in Design Therapeutics Inc. with AI2025 Geopolitical Influence & AI Based Buy/Sell Signal Reports - Newser
How institutional ownership impacts Design Therapeutics Inc. stockEarnings Miss & Daily Volume Surge Trade Alerts - Newser
Why Design Therapeutics Inc. is moving todayWeekly Trend Report & Fast Gain Stock Tips - Newser
Will Design Therapeutics Inc. continue its uptrendJuly 2025 Momentum & Risk Controlled Swing Trade Alerts - Newser
Design Therapeutics Inc. stock chart pattern explainedJuly 2025 Highlights & Real-Time Buy Signal Notifications - Newser
Institutional scanner results for Design Therapeutics Inc.Trade Performance Summary & Growth Focused Stock Pick Reports - Newser
Can volume confirm reversal in Design Therapeutics Inc.Swing Trade & Free Expert Verified Stock Movement Alerts - Newser
Is Design Therapeutics Inc. stock reversal real or fakeLong Setup & Real-Time Chart Breakout Alerts - Newser
Predicting Design Therapeutics Inc. trend using moving averagesMarket Performance Summary & AI Enhanced Trade Execution Alerts - Newser
What to expect from Design Therapeutics Inc. in the next 30 daysRecession Risk & Safe Entry Trade Signal Reports - Newser
Advanced analytics toolkit walkthrough for Design Therapeutics Inc.2025 Earnings Surprises & Technical Pattern Recognition Alerts - Newser
Design Therapeutics appoints former GW Pharmaceuticals CEO to board - Investing.com
Design Therapeutics Appoints Justin Gover to Board of Directors - Investing News Network
Design Therapeutics Appoints Justin Gover as Director - TipRanks
Design Therapeutics Appoints Justin Gover to Board of Directors Amid Strategic Growth - Quiver Quantitative
$7B GW Pharma Exit Veteran Justin Gover Joins Design Therapeutics Board to Advance Genetic Disease Pipeline - Stock Titan
How to track smart money flows in Design Therapeutics Inc.2025 Earnings Impact & Accurate Intraday Trading Signals - Newser
Will Design Therapeutics Inc. rebound enough to break evenJuly 2025 Highlights & Fast Entry High Yield Tips - Newser
What technical models suggest about Design Therapeutics Inc.’s comebackJuly 2025 Breakouts & Reliable Trade Execution Plans - Newser
Aug PreEarnings: Is Design Therapeutics Inc. attractive for institutional investors2025 Pullback Review & Weekly Return Optimization Alerts - Lancaster City Council
Using data models to predict Design Therapeutics Inc. stock movementPortfolio Value Report & Real-Time Volume Analysis Alerts - Newser
Nuveen LLC Makes New Investment in Design Therapeutics, Inc. $DSGN - MarketBeat
Historical volatility pattern of Design Therapeutics Inc. visualized2025 Analyst Calls & Entry Point Strategy Guides - Newser
Understanding Design Therapeutics Inc.’s price movementJuly 2025 Reactions & Safe Capital Preservation Plans - Newser
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):